Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06517641 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
A Phase 2 study of Severe Aplastic Anemia, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06517641: Recruiting Phase 2 study of Severe Aplastic Anemia, sponsored by Medical College of Wisconsin.
NCT06517641 is a Phase 2 study of Severe Aplastic Anemia that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 60 participants, below the 123-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06517641, a Phase 2 study of Severe Aplastic Anemia, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
Primary Outcome
The primary endpoint is GFFS at 1 year after initiation of conditioning. Events for GFFS include Grade III-IV aGVHD, cGVHD requiring immunosuppression, primary or secondary graft failure requiring second definitive therapy, failure to receive an HSCT infusion, and death. GFFS is defined as the time interval from start of conditioning until the first of these events occurs. For failure to receive an HSCT infusion, the date will be at the time the decision not to proceed to HSCT is made.
Conditions Studied
Interventions
- DRUG Haploidentical donor bone marrow transplant
- DRUG Unrelated donor bone marrow transplant
Study Locations (20)
California
- City of Hope - Duarte
- University of California, Los Angeles - Los Angeles
- Stanford University - Stanford
North Carolina
- UNC Chapel Hill - Chapel Hill
- Levine Cancer Institute - Charlotte
- Duke University Health System - Durham
Georgia
- Emory Winship Cancer Institute - Atlanta
- Blood and Marrow Transplant Center at Northside Hospital - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Alabama
- University of Alabama at Birmingham - Birmingham
Florida
- Moffitt Cancer Center - Tampa
Kansas
- University of Kansas Medical Center - Westwood
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2029-02-01 |
| Phase | Phase 2 |
What NCT06517641 shows while recruiting
NCT06517641 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 123-participant average among 16 other Severe Aplastic Anemia trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Severe Aplastic Anemia appearing as the primary indexed condition, and to 2 interventions - of which Haploidentical donor bone marrow transplant is the first listed.
NCT06517641 names 20 study sites across 14 states, led by California, North Carolina, Georgia.
Frequently Asked Questions
What is clinical trial NCT06517641 about?
NCT06517641 is a clinical study titled "Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia". BMT CTN 2207 will investigate the use of marrow transplantation for treatment of severe aplastic anemia that has not previously been treated.
What is the current status of trial NCT06517641?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-05-12. Estimated completion is 2029-02-01.
What conditions does trial NCT06517641 study?
This clinical trial studies the following conditions: Severe Aplastic Anemia.
What interventions are being tested in trial NCT06517641?
The interventions under investigation include: Haploidentical donor bone marrow transplant (DRUG), Unrelated donor bone marrow transplant (DRUG).
Who is sponsoring clinical trial NCT06517641?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06517641 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Aplastic Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06517641's enrollment target sits among peer trials
60 7th of 16 higher than 9 of 16 other Severe Aplastic Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Aplastic Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
RECRUITING · Phase 2
-
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
RECRUITING · Phase 2
-
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
RECRUITING · Phase 2
-
Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
RECRUITING · Phase 2
-
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
RECRUITING · Phase 2
-
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI